Home Angiogenesis FLT3 inhibitor - c-Kit inhibitor - FGFR inhibitor - PDGFR inhibitor - VEGFR inhibitor Dovitinib (TKI-258) For research use only.

Dovitinib (TKI-258)

Synonyms: CHIR-258

Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.

Dovitinib (TKI-258) Chemical Structure

Dovitinib (TKI-258) Chemical Structure

CAS: 405169-16-6

Selleck's Dovitinib (TKI-258) has been cited by 50 publications

Purity & Quality Control

Batch: Purity: 99.98%
99.98

Other FLT3 Products

Related compound libraries

Choose Selective FLT3 Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SupB15 Growth Inhibition Assay IC50=0.449 μM 25202073
SupB15-R Growth Inhibition Assay IC50=0.558 μM 25202073
BaF3-pSRα Growth Inhibition Assay IC50=0.668 μM 25202073
BaF3-p210Bcr-Abl Growth Inhibition Assay IC50=0.692 μM 25202073
BaF3-p210Bcr-Abl-T315I Growth Inhibition Assay IC50=2.626 μM 25202073
CCRF-CEM Growth Inhibition Assay IC50=0.398 μM 25202072
CEM/C2 Growth Inhibition Assay IC50=1.125 μM 25202072
Nalm-6 Growth Inhibition Assay IC50=0.382 μM 25202072
SEM-K2 Growth Inhibition Assay IC50=0.022 μM 25202072
HB-1119 Growth Inhibition Assay IC50=0.028 μM 25202072
RS4:11 Growth Inhibition Assay IC50=2.81 μM 25202072
Nalm-6 Apoptosis Assay 2 μM 24/48 h induces apoptosis resulting in about 72% of cell death after 24 h treatment and 81% after 48 h 25202072
SEM-K2 Apoptosis Assay 0.1/1 μM 24 h induces early apoptosis of SEM-K2 cells at 0.1 μM after 24 h 25202072
HCT-116 Growth Inhibition Assay IC50=3.050.58 μM 24495750
HT-29 Growth Inhibition Assay IC50=5.21.93 μM 24495750
SW-480 Growth Inhibition Assay IC50=4.330.47 μM 24495750
CaCO2 Growth Inhibition Assay IC50=3.230.64 μM 24495750
LS174T Growth Inhibition Assay IC50=4.330.47 μM 24495750
HEC-1A Function Assay 0.05/0.1/0.5 μM 72 h causes a decrease in STAT3, ERK, and AKT phosphorylation 24495750
AN3CA Function Assay 0.05/0.1/0.5 μM 72 h causes a decrease in STAT3, ERK, and AKT phosphorylation 24495750
MFE-296  Function Assay 0.05/0.1/0.5 μM 72 h causes a decrease in STAT3, ERK, and AKT phosphorylation 24495750
UMC3 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
5637 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
HU456 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
MGHU4 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
HT1376 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
RT112 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
T24 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
BFTC905 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
TCC-SUP Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
RT4 Cell Viability Assay 1-10 μM 72 h inhibits cell growth in a dose dependent manner 24325461
HONE1 Growth Inhibition Assay 0.1-10 μM 48 h induces G2/M delay in a concentration-dependent manner 24238094
HNE1 Growth Inhibition Assay 0.1-10 μM 48 h induces G2/M delay in a concentration-dependent manner 24238094
CNE2  Growth Inhibition Assay 0.1-10 μM 48 h induces G2/M delay in a concentration-dependent manner 24238094
C666-1 Growth Inhibition Assay 0.1-10 μM 48 h induces G2/M delay in a concentration-dependent manner 24238094
HeLa Growth Inhibition Assay 0.1-10 μM 24 h induces G2/M arrest in a concentration-dependent manner 24238094
Hep3B Growth Inhibition Assay 0.1-10 μM 24 h induces G2 arrest  24238094
HepG2 Growth Inhibition Assay 48 h IC50=2.727 ± 0.429 μM 23546591
Hep3B Growth Inhibition Assay 48 h IC50=4.223 ± 0.839 μM 23546591
PLC/PRF5 Growth Inhibition Assay 48 h IC50=16.120 ± 4.001 μM 23546591
Huh7 Growth Inhibition Assay 48 h IC50=15.007 ± 7.334 μM 23546591
HepG2 Growth Inhibition Assay 72 h IC50=1.200 ± 0.226 μM 23546591
Hep3B Growth Inhibition Assay 72 h IC50=0.892 ± 0.044 μM 23546591
PLC/PRF5 Growth Inhibition Assay 72 h IC50=3.110 ± 0.337 μM 23546591
Huh7 Growth Inhibition Assay 72 h IC50=3.980 ± 0.803 μM 23546591
MFE280 Growth Inhibition Assay IC50=0.42 ± 0.06 μM 23443805
AN3CA Growth Inhibition Assay IC50=0.50 ± 0.10 μM 23443805
HEC155 Growth Inhibition Assay IC50=0.66 ± 0.09 μM 23443805
MFE296 Growth Inhibition Assay IC50=0.66 ± 0.19 μM 23443805
SPAC1S Growth Inhibition Assay IC50=0.77 ± 0.08 μM 23443805
RL952 Growth Inhibition Assay IC50=0.93 ± 0.01 μM 23443805
EN1 Growth Inhibition Assay IC50=1.02 ± 0.25 μM 23443805
SNGII Growth Inhibition Assay IC50=1.24 ± 0.28 μM 23443805
ISHIKAWA Growth Inhibition Assay IC50=1.30 ± 0.11 μM 23443805
HEC1A Growth Inhibition Assay IC50=1.34 ± 0.30 μM 23443805
KLE Growth Inhibition Assay IC50=1.37 ± 0.02 μM 23443805
SNGM Growth Inhibition Assay IC50=1.42 ± 0.13 μM 23443805
USPC2 Growth Inhibition Assay IC50=1.62 ± 0.01 μM 23443805
EN Growth Inhibition Assay IC50=1.66 ± 0.01 μM 23443805
MFE319 Growth Inhibition Assay IC50=1.87 ± 0.45 μM 23443805
EFE184 Growth Inhibition Assay IC50=2.04 ± 0.13 μM 23443805
ECC1 Growth Inhibition Assay IC50=2.07 ± 0.01 μM 23443805
HEC1B Growth Inhibition Assay IC50=2.57 ± 0.23 μM 23443805
USPC1 Growth Inhibition Assay IC50=2.60 ± 0.13 μM 23443805
SPAC1L Growth Inhibition Assay IC50=3.06 ± 1.14 μM 23443805
HUVEC Cell Viability Assay 0-25 μM 72 h DMSO inhibits cell growth in a dose dependent manner 23228017
HMVEC Cell Viability Assay 0-25 μM 72 h DMSO inhibits cell growth in a dose dependent manner 23228017
MHCC-97H Cell Viability Assay 0-25 μM 72 h DMSO inhibits cell growth in a dose dependent manner 23228017
SMMC7721 Cell Viability Assay 0-25 μM 72 h DMSO inhibits cell growth in a dose dependent manner 23228017
Huh-7 Apoptosis Assay 0-12.5 μM 24 h DMSO  sensitizes HCC cells to TRAIL- and tigatuzumab-induced apoptosis in a dose-dependent manner 22230479
Sk-Hep1 Apoptosis Assay 0-12.5 μM 24 h DMSO  sensitizes HCC cells to TRAIL- and tigatuzumab-induced apoptosis in a dose-dependent manner 22230479
Hep3B Apoptosis Assay 0-12.5 μM 24 h DMSO  sensitizes HCC cells to TRAIL- and tigatuzumab-induced apoptosis in a dose-dependent manner 22230479
PLC5 Apoptosis Assay 0-12.5 μM 24 h DMSO  sensitizes HCC cells to TRAIL- and tigatuzumab-induced apoptosis in a dose-dependent manner 22230479
PLC5 Cell Viability Assay 0-15 μM 72 h reduces cell viability in a dose-dependent manner  22180308
Hep3B Cell Viability Assay 0-15 μM 72 h reduces cell viability in a dose-dependent manner  22180308
Sk-Hep1 Cell Viability Assay 0-15 μM 72 h reduces cell viability in a dose-dependent manner  22180308
Huh-7 Cell Viability Assay 0-15 μM 72 h reduces cell viability in a dose-dependent manner  22180308
PLC5 Apoptosis Assay 0-15 μM 24 h increases apoptotic cell death in a dose-dependent manner  22180308
Hep3B Apoptosis Assay 0-15 μM 24 h increases apoptotic cell death in a dose-dependent manner  22180308
Sk-Hep1 Apoptosis Assay 0-15 μM 24 h increases apoptotic cell death in a dose-dependent manner  22180308
Huh-7 Apoptosis Assay 0-15 μM 24 h increases apoptotic cell death in a dose-dependent manner  22180308
PLC5 Function Assay 0-10 μM 24 h causes dose-dependent DNA fragmentation 22180308
Hep3B Function Assay 0-10 μM 24 h causes dose-dependent DNA fragmentation 22180308
Sk-Hep1 Function Assay 0-10 μM 24 h causes dose-dependent DNA fragmentation 22180308
Huh-7 Function Assay 0-10 μM 24 h causes dose-dependent DNA fragmentation 22180308
SW780 Growth Inhibition Assay 5 d IC50=50 nM 21119661
RT112 Growth Inhibition Assay 5 d IC50=15 nM 21119661
RT4 Growth Inhibition Assay 5 d IC50=5 nM 21119661
JMSU1 Growth Inhibition Assay 5 d IC50=50 nM 21119661
J82 Growth Inhibition Assay 5 d IC50=1400 nM 21119661
97-7 Growth Inhibition Assay 5 d IC50=1000 nM 21119661
RT112 Function Assay 500 nM 24 h increases the proportion of cells in G1 accompanied by a decrease in S and G2/M phases 21119661
RT4 Function Assay 500 nM 24 h increases the proportion of cells in G1 accompanied by a decrease in S and G2/M phases 21119661
MGH-U3 Function Assay 500 nM 24 h increases the proportion of cells in G1 accompanied by a decrease in S and G2/M phases 21119661
SW780 Function Assay 500 nM 24 h increases the proportion of cells in G1 accompanied by a decrease in S and G2/M phases 21119661
97-7 Function Assay 500 nM 24 h increases the proportion of cells in G1 accompanied by a decrease in S and G2/M phases 21119661
 J807C Cell Viability Assay 0-400 nM 48 h inhibits cell growth in a dose dependent manner 15598814
Y373C Cell Viability Assay 0-400 nM 48 h inhibits cell growth in a dose dependent manner 15598814
K650E Cell Viability Assay 0-400 nM 48 h inhibits cell growth in a dose dependent manner 15598814
G384D Cell Viability Assay 0-400 nM 48 h inhibits cell growth in a dose dependent manner 15598814
F384L Cell Viability Assay 0-400 nM 48 h inhibits cell growth in a dose dependent manner 15598814
KMS11 Growth Inhibition Assay 72 h IC50=90 nM 15598814
KMS18 Growth Inhibition Assay 72 h IC50=550 nM 15598814
OPM2 Growth Inhibition Assay 72 h IC50=90 nM 15598814
H929 Growth Inhibition Assay 72 h IC50> 2500 nM 15598814
8226 Growth Inhibition Assay 72 h IC50> 2500 nM 15598814
U266 Growth Inhibition Assay 72 h IC50> 2500 nM 15598814
KM12L4A Function assay Inhibition of VEGFR2 phosphorylation expressed in human KM12L4A cells by Western blot analysis, EC50=0.046μM 19113866
KM12L4A Function assay Inhibition of PDGFRbeta phosphorylation expressed in human KM12L4A cells Western blot analysis, EC50=0.051μM 19113866
KM12L4A Function assay Inhibition of FGFR1 phosphorylation expressed in human KM12L4A cells by Western blot analysis, EC50=0.166μM 19113866
insect cells Function assay 1 to 4 hrs Inhibition of recombinant PDGFRbeta (unknown origin) expressed in baculovirus infected insect cells using biotinylated peptide substrate GGLFDDPSYVNVQNL in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescence assay, IC50=0.001μM 27914362
Sf9 Function assay 1 to 4 hrs Inhibition of recombinant human N-terminal GST/His6-tagged c-KIT (544 to 976 residues) expressed in baculovirus infected sf9 cells using biotinylated peptide substrate GGLFDDPSYVNVQNL in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescen, IC50=0.001μM 27914362
Sf9 Function assay 1 to 4 hrs Inhibition of recombinant human N-terminal GST/His6-tagged FLT3 (571 to 993 residues) expressed in baculovirus infected sf9 cells using biotinylated peptide substrate GGLFDDPSYVNVQNL in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescenc, IC50=0.001μM 27914362
insect cells Function assay 1 to 4 hrs Inhibition of recombinant FGFR1 (unknown origin) expressed in baculovirus infected insect cells using biotinylated peptide substrate GGGGQDGKDYIVLPI in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescence assay, IC50=0.008μM 27914362
insect cells Function assay 1 to 4 hrs Inhibition of recombinant VEGFR3 (unknown origin) expressed in baculovirus infected insect cells using biotinylated peptide substrate GGGGQDGKDYIVLPI in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescence assay, IC50=0.008μM 27914362
insect cells Function assay 1 to 4 hrs Inhibition of recombinant VEGFR1 (unknown origin) expressed in baculovirus infected insect cells using biotinylated peptide substrate GGGGQDGKDYIVLPI in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescence assay, IC50=0.01μM 27914362
insect cells Function assay 1 to 4 hrs Inhibition of recombinant VEGFR2 (unknown origin) expressed in baculovirus infected insect cells using biotinylated peptide substrate GGGGQDGKDYIVLPI in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescence assay, IC50=0.013μM 27914362
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
insect cells Function assay 1 to 4 hrs Inhibition of recombinant FGFR1 (unknown origin) expressed in baculovirus infected insect cells using GGGGQDGKDYIVLPI as substrate after 1 to 4 hrs by time-resolved fluorescence assay, IC50=0.008μM 30503938
NCI-H1703 Function assay 10 uM 24 hrs Inhibition of TNIK in human NCI-H1703 cells transfected with lentiviral vector 7TFP assessed as reduction of GSK3 inhibitor X activated TNIK-mediated Wnt/TCF/beta-catenin-dependent transcription at 10 uM after 24 hrs by luciferase reporter assay ChEMBL
LoVo Cytotoxicity assay 10 uM 72 hrs Cytotoxicity against Wnt/beta-catenin signalling dependent human LoVo cells assessed as cell viability at 10 uM after 72 hrs by ATPlite assay ChEMBL
HCT116 Cytotoxicity assay 10 uM 72 hrs Cytotoxicity against Wnt/beta-catenin signalling dependent human HCT116 cells assessed as cell viability at 10 uM after 72 hrs by ATPlite assay ChEMBL
Click to View More Cell Line Experimental Data

Biological Activity

Description Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.
Targets
FLT3 [1]
(Cell-free assay)		 c-Kit [1]
(Cell-free assay)		 FGFR1 [1]
(Cell-free assay)		 VEGFR3/FLT4 [1]
(Cell-free assay)		 FGFR3 [1]
(Cell-free assay)		 Click to View More Targets
1 nM 2 nM 8 nM 8 nM 9 nM
In vitro
In vitro Dovitinib potently inhibits the FGF-stimulated growth of WT and F384L-FGFR3-expressing B9 cells with IC50 of 25 nM. In addition, Dovitinib inhibits proliferation of B9 cells expressing each of the various activated mutants of FGFR3. Interestingly, there are minimal observed differences in the sensitivity of the different FGFR3 mutations to Dovitinib, with the IC50 ranging from 70 to 90 nM for each of the various mutations. IL-6-dependent B9 cells containing vector only (B9-MINV cells are resistant to the inhibitory activity of Dovitinib at concentrations up to 1 μM. Dovitinib inhibits cell proliferation of KMS11 (FGFR3-Y373C), OPM2 (FGFR3-K650E), and KMS18 (FGFR3-G384D) cells with IC50 of 90 nM (KMS11 and OPM2) and 550 nM, respectively. Dovitinib inhibits FGF-mediated ERK1/2 phosphorylation and induces cytotoxicity in FGFR3-expressing primary MM cells. BMSCs does confer a modest degree of resistance with 44.6% growth inhibition for cells treated with 500 nM Dovitinib and cultured on stroma compared with 71.6% growth inhibition for cells grown without BMSCs. Dovitinib inhibits proliferation of M-NFS-60, an M-CSF growth-driven mouse myeloblastic cell line with a median effective concentration (EC50) of 220 nM. [1] Treatment of SK-HEP1 cells with Dovitinib results in a dose-dependent reduction in cell number and G2/M phase arrest with reduction in the G0/G1 and S phases, inhibition of anchorage-independent growth and blockage of bFGF-induced cell motility. The IC50 for Dovitinib in SK-HEP1 cells is approximately 1.7 μM. Dovitinib also significantly reduces the basal phosphorylation levels of FGFR-1, FGFR substrate 2α (FRS2-α) and ERK1/2 but not Akt in both SK-HEP1 and 21-0208 cells. In 21-0208 HCC cells, Dovitinib significantly inhibits bFGF-induced phosphorylation of FGFR-1, FRS2-α, ERK1/2 but not Akt. [2]
Kinase Assay In vitro kinase assays
The inhibitory concentration of 50% (IC50) values for the inhibition of RTKs by Dovitinib are determined in a time-resolved fluorescence (TRF) or radioactive format, measuring the inhibition by Dovitinib of phosphate transfer to a substrate by the respective enzyme. The kinase domains of FGFR3, FGFR1, PDGFRβ, and VEGFR1-3 are assayed in 50 mM HEPES (N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid), pH 7.0, 2 mM MgCl2, 10 mM MnCl2 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mg/mL bovine serum albumin (BSA), 0.25 μM biotinylated peptide substrate (GGGGQDGKDYIVLPI), and 1 to 30 μM adenosine triphosphate (ATP) depending on the Km for the respective enzyme. ATP concentrations are at or just below Km. For c-KIT and FLT3 reactions the pH is raised to 7.5 with 0.2 to 8 μM ATP in the presence of 0.25 to 1 μM biotinylated peptide substrate (GGLFDDPSYVNVQNL). Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mM HEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled antiphosphotyrosine antibody PT66. The concentration of Dovitinib for IC50 is calculated using nonlinear regression with XL-Fit data analysis software version 4.1 (IDBS). Inhibition of colony-stimulating factor-1 receptor (CSF-1R), PDGFRα, insulin receptor (InsR), and insulin-like growth factor receptor 1 (IGFR1) kinase activity is determined at ATP concentrations close the Km for ATP.
Cell Research Cell lines B9 cells, MM cell lines
Concentrations 100 nM
Incubation Time 48-96 hours
Method Cell viability is assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance. Cells are seeded in 96-well plates at a density of 5 × 103 (B9 cells) or 2 × 104 (MM cell lines) cells per well. Cells are incubated with 30 ng/mL aFGF and 100 μg/mL heparin or 1% IL-6 where indicated and increasing concentrations of Dovitinib. For each concentration of Dovitinib, 10 μL aliquots of drug or DMSO diluted in culture medium is added. For drug combination studies, cells are incubated with 0.5 μM dexamethasone, 100 nM Dovitinib, or both simultaneously where indicated. To evaluate the effect of Dovitinib on growth of MM cells adherent to BMSCs, 104 KMS11 cells are cultured on BMSC-coated 96-well plates in the presence or absence of Dovitinib. Plates are incubated for 48 to 96 hours. For assessment of macrophage colony-stimulating factor (M-CSF)-mediated growth, 5 × 103 M-NFS-60 cells/well are incubated with serial dilutions of Dovitinib with 10 ng/mL M-CSF and without granulocyte-macrophage colony-stimulating factor (GM-CSF). After 72 hours cell viability is determined using Cell Titer-Glo Assay. Each experimental condition is performed in triplicate.
Experimental Result Images Methods Biomarkers Images PMID
Western blot CDK1 / p-CDK1 / p53 / p21 p-PDGFR-β / PDGFR-β / p-ERK / ERK p-VEGFR-2 / VEGFR-2 / p-FGFR-1 / FGFR-1 p-STAT3 / STAT3 / Mcl-1 / LC3 / Beclin 1 / p62 24238094
Growth inhibition assay Cell viability 28467797
In Vivo
In vivo Dovitinib induces both cytostatic and cytotoxic responses in vivo resulting in regression of FGFR3-expressing tumors.[1] Dovitinib shows a dose- and exposure-dependent inhibition of target receptor tyrosine kinases (RTKs) expressed in tumor xenografts. Dovitinib potently inhibits tumor growth of six HCC lines. Inhibition of angiogenesis correlated with inactivation of FGFR/PDGFRβ/VEGFR2 signaling pathways. In an orthotopic model, Dovitinib potently inhibits primary tumor growth and lung metastasis and significantly prolonged mouse survival. [2] Administration of Dovitinib results in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm3). [3]
Animal Research Animal Models 8-week-old female BNX mice bearing KMS11 cells
Dosages 10, 30, or 60 mg/kg
Administration Gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05571969 Recruiting Advanced Solid Tumors Allarity Therapeutics|Amarex Clinical Research February 20 2023 Phase 1
NCT02268435 Withdrawn Gastrointestinal Stromal Tumors Asan Medical Center March 2015 Phase 1
NCT01700270 Completed Advanced Solid Tumors Excluding Breast Cancer Novartis Pharmaceuticals|Novartis May 2013 Phase 1
NCT01680796 Withdrawn Multiple Myeloma University of Florida|Novartis Pharmaceuticals February 2013 Phase 1
NCT01266070 Terminated Von Hippel-Lindau Syndrome M.D. Anderson Cancer Center|Novartis November 2012 Phase 2

Chemical lnformation & Solubility

Molecular Weight 392.43 Formula

C21H21FN6O
CAS No. 405169-16-6 SDF Download Dovitinib (TKI-258) SDF
Smiles CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 30 mg/mL ( (76.44 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Dovitinib (TKI-258) | Dovitinib (TKI-258) supplier | purchase Dovitinib (TKI-258) | Dovitinib (TKI-258) cost | Dovitinib (TKI-258) manufacturer | order Dovitinib (TKI-258) | Dovitinib (TKI-258) distributor